Introduction
============

Hepatocellular carcinoma (HCC) is the most frequent tumor type of primary liver cancer, accounting for the third highest cause of cancer-related deaths.[@b1-ott-11-8175] HCC usually occurs subsequently to liver cirrhosis caused by sustained alcohol intake or to chronic hepatitis virus (HBV, HCV, etc) infection.[@b2-ott-11-8175] HCC is characterized by its high rate of distant metastasis and tumor recurrence, even after curative resection treatment.[@b3-ott-11-8175] Accordingly, HCC is a highly malignant tumor type, and the 5-year overall survival (OS) is reported to be 30%--50%.[@b4-ott-11-8175] Therefore, identifying novel biomarkers for predicting prognosis and chemotherapy treatment is of great importance. Although multiple tumor biomarkers have been reported to regulate HCC occurrence and progression, our knowledge on its underlying molecular mechanisms remains limited.

Besides conventional protein markers, recent advances in genomics and metabolomics have made great contributions to the identification of novel tumor biomarkers. miRNAs are endogenous noncoding RNAs comprisinĝ20 nucleotides.[@b5-ott-11-8175] Their general function is to inhibit the protein expression by binding to the 3′-untranslated region (UTR) of targeted mRNAs.[@b6-ott-11-8175] By modulating RNA modification and protein translation, microRNAs are considered critical in human diseases including tumor development.[@b7-ott-11-8175] Moreover, more and more microRNAs are acknowledged as tumor biomarkers; they can help not only diagnose tumor occurrence and distinguish tumor subtype but also predict patients' prognosis.[@b8-ott-11-8175] The advantages of microRNAs as clinically potential markers include their stable properties and their feasibility to be detected by high-throughput strategies. For example, the miR-302 has been reported to be a prognostic biomarker in several tumor types, including glioma,[@b9-ott-11-8175] renal carcinoma,[@b10-ott-11-8175] and gastric cancer.[@b11-ott-11-8175] Of note, miR-302 was recently revealed to inhibit the endothelial--mesenchymal transition of endothelial cells, thus indirectly regulating the progression of HCC according to cellular experiments.[@b12-ott-11-8175] However, whether miR-302a-3p was aberrantly expressed in HCC tissues and its direct effect on HCC progression have not been investigated.

Here, in this study, we first explored the expression of miR-302a-3p in HCC tissues and statistically analyzed its clinical significance as a novel prognostic biomarker. Furthermore, we conducted cellular experiments by overexpressing miR-302a-3p mimics to better illustrate its tumor-promoting role in HCC development.

Patients and methods
====================

Patients and tissues
--------------------

This study was approved by the ethics committee of The Seventh People's Hospital. A total of 111 HCC tissues and paired adjacent specimens were collected from the Department of Pathology in our hospital. The usage of tissue samples was conducted after obtaining all written informed consents from corresponding patients. All tissues were resected between 2009 and 2013 and embedded in paraffin. The inclusion criteria included a precise pathological diagnosis without any preoperative therapy, as well as the availability of follow-up data.

miRNA extraction and real-time quantitative polymerase chain reaction (RT-qPCR)
-------------------------------------------------------------------------------

miRNAs were extracted from tissues using a miRNeasy mini kit (Qiagen NV, Venlo, the Netherlands) according to the manufacturer's instructions. The quality and concentration of isolated RNAs were confirmed by a NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific). A total amount of 50 ng RNAs was reversely transcribed into cDNA using a TaqMan miRNA Reverse Transcription Kit (Thermo Fisher Scientific) according to the standard protocol. The RT-qPCR was performed using a real-time polymerase chain reaction (PCR) instrument (Thermo Fisher Scientific) using the primers as follows: miR-302a-3p forward: 5′-AATAAGTGCTTCCATGTTTTGGTGA-3′[@b13-ott-11-8175] and GAPDH forward: 5′-GCCGCATCTTCTTTTGCGTCGC-3′, reverse: 5′-TCCCGTTCTCAGCCTTGACGGT-3′.[@b14-ott-11-8175] The level of miR-302a-3p was evaluated using the comparative *C*~t~ method (ΔΔ*C*~t~) and normalized by the GAPDH level.

Cell culture and transfection
-----------------------------

The human HCC cell lines HepG2 and Huh7 were both obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in DMEM supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific) and 1% penicillin/streptomycin at 37°C with 5% CO~2~.

The miR-302a-3p mimics and miR-negative control were ordered from GenePharma (Shanghai, People's Republic of China). All the transfections were performed using Lipofectamine 2000 and then incubated in the incubator for 6 h. The cell culture medium was then replaced with the fresh medium containing 10% FBS. After cultured for 24--48 h, cells were subjected to functional assays.

Proliferation assay
-------------------

MTT assay was used to measure the proliferation of HCC cells. Briefly, transfected cells were seeded onto a 96-well plate at a density of 1,000 cells/well in triplicate and cultured in DMEM containing 10% FBS. At the indicated time points (24, 48, 72, and 96 h), 20 μL of 5 mg/mL MTT was added to each well, and the cells were incubated for another 4 h at 37°C. Then, 200 μL of dimethyl sulfoxide (DMSO) was added per well to the cultured cells to dissolve the crystals. The absorbance was measured at 490 nm with a reference wavelength at 655 nm using a microplate reader (Bio-Rad Laboratories Inc., Hercules, CA, USA). The experiment was repeated three times independently. All the data were analyzed and plotted using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA).

Migration and invasion assays
-----------------------------

Transwell chambers (8 μM, 24-well plate; EMD Millipore, Billerica, MA, USA) were used to measure the migration ability of HCC cells. Briefly, 2×10^4^ cells were seeded into the upper chambers containing serum-free DMEM. The lower chamber was supplemented with 500 μL DMEM containing 10% FBS. After 24 h culture in the incubator, the membrane was carefully cleaned using a cotton swab to remove non-migrated cells, and cells that located on the bottom surface were fixed with 1% paraformaldehyde and then stained with 0.1% crystal violet. The invaded cell numbers were quantified by counting using a light microscope from five random fields for each well.

For the invasion assay, the transwell chambers were pre-coated with 50 μg Matrigel (BD Biosciences, San Jose, CA, USA), and then, 5×10^4^ cells were seeded into each chamber. The subsequent procedures were same as those for migration analysis. All experiments were performed in triplicate and repeated for at least three times.

Plasmid, transfection, and luciferase activity assays
-----------------------------------------------------

The PRKACB plasmid was purchased from Addgene, Cambridge, MA, USA and subcloned into pGL3 luciferase vector; the mutant of PRKACB was constructed by site-specific mutagenesis strategy.

HepG2 cells were seeded into a 24-well plate at the density of 1×10^4^ cells/well. Cells were transfected with both miR302a-3p and PRKACB plasmids using Lipofectamine 2000 transfection reagent.[@b15-ott-11-8175] Briefly, a blank vector was introduced as the control of miR302a-3p, which was also co-transfected with either PRKACB-wild type (WT) or PRKACB-mutant plasmids containing firefly luciferase. The value of relative luciferase activity was evaluated by a dual luciferase assay kit (Promega Corporation, Fitchburg, WI, USA) according to the manufacturer's instructions.

Western blot
------------

The Western blot was conducted to test the protein expression levels as described by others.[@b16-ott-11-8175] Briefly, cultured cells were lysed using radioimmunoprecipitation assay (RIPA) buffer supplemented with protease inhibitor cocktails (Hoffman-La Roche Ltd., Basel, Switzerland). After determining the extracted protein concentration by a Pierce BCA protein quantification kit (Thermo Fisher Scientific), 20 μg of total proteins were separated by 12% sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. After blocking with 5% bovine serum albumin in Tris Buffered Saline with Tween 20, the nitrocellulose membranes were incubated with primary antibodies at 4°C overnight. Corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies were added and allowed for another 1 h incubation at room temperature, and the immunoreactivity was finally detected by using X-ray film.

Statistics
----------

Statistical analyses were carried out by using SPSS 20.0 (IBM Corporation, Armonk, NY, USA) and GraphPad Prism 5.0 software. Chi-square test was used to compare the statistical difference of two groups. OS time was defined as the period from the date of surgery to death or the end of follow-up (July 2017). The OS curves were plotted by the Kaplan-- Meier method and compared by the logrank test. Univariate and multivariate Cox regression analyses were performed to explore the clinical significance of different variables. After confirming the distribution normality using the Shapiro-- Wilk test and the variance homogeneity by the Levene's test (all *P*\>0.05), data from cellular experiments were analyzed using the Student's *t*-test to assess the differences between groups. All data were represented as mean±SD, and *P*\<0.05 was considered as statistically significant.

Results
=======

Patients' information
---------------------

We enrolled 111 HCC patients in this study; all patients were pathologically diagnosed with HCC, and none of them received any antitumor therapy before surgery resection. All the surgery treatment was R0 resection. The median age of the patients at the time of surgery was 47 years. Most of the patients were male (91/111, 82.0%). As all the patients were collected in China, where hepatitis virus infection is the major cause of HCC, we thus retrieved the information about HBV infection. Accordingly, 87 (78.4%) patients were tested with HBV positive at the time of diagnosis. In all, 72 (64.9%) patients showed a higher serum AFP level (\>400 U/mL). The information about the number of primary HCC and the largest tumor diameter was also collected. Most of the patients suffered from single tumor (72/111, 64.9%), and 62.2% patients had a tumor diameter \>5.0 cm. Additionally, 31 (27.9%) patients showed tumor infiltration in portal vein, and 67 (60.4%) patients were classified to have TNM stage III/IV ([Table 1](#t1-ott-11-8175){ref-type="table"}).

miR-302a-3p is downregulated in HCC tissues and correlated with tumor progression
---------------------------------------------------------------------------------

We tested the tissue expression levels of miR-302a-3p by RT-qPCR in both HCC tumor tissues and adjacent normal liver tissues. Most of the patients (74/111, 66.7%) showed a lower miR-302a-3p level in HCC tissues compared with that in normal liver tissues ([Figure 1A and B](#f1-ott-11-8175){ref-type="fig"}). The chi-square test was next conducted to compare differential expression of miR-302a-3p in various subgroups. As a result, a lower miR-302a-3p level was correlated with multiple tumor involvement (*P*=0.003) and a larger tumor size (*P*\<0.001). In addition, patients with advanced tumor stages were characterized with lower miR-302a-3p levels (*P*=0.028; [Table 2](#t2-ott-11-8175){ref-type="table"}), suggesting the possible tumor-suppressing role of miR-302a-3p in HCC development.

Low miR-302a-3p is an independent biomarker for predicting a poorer OS of HCC
-----------------------------------------------------------------------------

To explore the role of miR-302a-3p in HCC prognosis, all the retrieved clinicopathological characteristics were subjected to Kaplan--Meier survival analyses ([Figure 2](#f2-ott-11-8175){ref-type="fig"} and [Table 3](#t3-ott-11-8175){ref-type="table"}). According to the univariate analysis and logrank test, prognostic factors included tumor number (*P*=0.006), tumor diameter (*P*=0.015), portal vein invasion (*P*=0.010), and TNM stage (*P*\<0.001). Importantly, patients with higher miR-302a-3p levels also showed better clinical outcomes than those with lower miR-302a-3p levels (3-year OS 58.7% vs 28.2%; mean OS 38.8±3.2 vs 25.6±1.7 months; *P*=0.002). In contrast, there was no significant correlation between OS and patients' age, sex, HBV infection, or serum AFP level.

The variables with statistical significance found by univariate analysis were next subjected to a Cox regression model to explore their independent prognostic effect ([Table 4](#t4-ott-11-8175){ref-type="table"}). Both the TNM stage (HR=2.339, 95% CI=1.748--4.290, *P*=0.024) and miR-302a-3p level (HR=0.480, 95% CI=0.249--0.894, *P*=0.039) were identified as independent prognostic factors. Taken together, clinical data showed that miR-302a-3p is a tumor suppressor in HCC and can help predict patients' OS.

miR-302a-3p inhibits proliferation, migration, and invasion capacities of HCC cells
-----------------------------------------------------------------------------------

We also performed cellular experiments in two human HCC cell lines, HepG2 and Huh7. After overexpressing miR-302a-3p mimics, both HCC cell lines showed a decreased cell proliferation pattern ([Figure 3A and B](#f3-ott-11-8175){ref-type="fig"}) as revealed by MTT assays. In addition, the cell migration ability was tested by transwell strategy, which showed that miR-302a-3p can inhibit HCC cell migration ([Figure 3C and D](#f3-ott-11-8175){ref-type="fig"}). Finally, the Matrigel transwell assay was performed to investigate whether miR-302a-3p had an effect on cell invasion. According to our data, transfection of miR-302a-3p mimics remarkably inhibited the tumor cell invasion ([Figure 3E and F](#f3-ott-11-8175){ref-type="fig"}), demonstrating its direct role in suppressing HCC progression.

miR-302a-3p targets PRKACB protein, thus inhibiting Src and CREB activation
---------------------------------------------------------------------------

We next aimed to explore the underlying mechanism of miR-302a-3p in inhibiting tumor progression of HCC. By using the TargetScan tool ([www.targetscan.org](http://www.targetscan.org)), we found that PRKACB, the catalytic subunit beta of PKA kinase, possesses a potential binding site with miR-302a-3p ([Figure 4A](#f4-ott-11-8175){ref-type="fig"}), which is consistent with a most recent study.[@b17-ott-11-8175] Furthermore, we verified that miR-302a-3p can directly regulate the transcription of PRKACB by using luciferase assays ([Figure 4B](#f4-ott-11-8175){ref-type="fig"}). In contrast, after mutating the binding sites on PRKACB, miR-302a-3p co-transfection showed little effect on its luciferase activity. Western blot results also showed that miR-302a-3p overexpression can inhibit the expression of PRKACB ([Figure 4C](#f4-ott-11-8175){ref-type="fig"}). Additionally, the activation of PKA downstream effectors such as Src and CREB oncoproteins was also inhibited by miR-302a-3p. Considering the regulatory role of Src and CREB on cancer progression,[@b18-ott-11-8175],[@b19-ott-11-8175] we proposed a signaling network on the PRKACB-dependent effect of miR-302a-3p on inhibiting HCC proliferation and invasion ([Figure 4D](#f4-ott-11-8175){ref-type="fig"}).

Discussion
==========

Accumulating evidence highlighted the critical role of miR-NAs in tumorigenesis and tumor development. miR-302 was first reported to be downregulated by 1,25(OH)~2~D~3~ treatment in several tumor cell lines, which resulted in a higher susceptibility to natural killer cell-mediated cytotoxicity.[@b20-ott-11-8175] Although this datum revealed a possible oncogenic effect of miR-302a-3p, it did not illustrate its functional mechanisms from the molecular aspect.

Additionally, later studies reported that miR-302a suppressed the endothelial--mesenchymal transition of endothelial cells, subsequently playing tumor suppressing roles by indirectly inhibiting HCC progression.[@b12-ott-11-8175] However, both the two studies mentioned earlier were based on "bench" findings, and the clinical significance of miR-302 was not recognized until 2015. Oksuz et al[@b21-ott-11-8175] implied that serum miR-302 could be used as a biomarker for predicting occurrence of cirrhosis and HCC in HCV-positive patients. Moreover, miR-302a-3p showed a direct inhibitory effect on the proliferation and invasion of glioma cells,[@b22-ott-11-8175] suggesting its role as a suppressor in solid tumors. Furthermore, it was recently reported that a low expression of miR-302a-3p was correlated with poorer survival of gastric cancer patients.[@b11-ott-11-8175] Therefore, we sought to investigate the clinical significance and functional mechanisms of miR-302a-3p in HCC.

According to our data, miR-302a-3p was significantly downregulated in HCC tissues compared with adjacent liver tissues. Clinical data revealed its statistical correlation with tumor size and TNM stage. We also demonstrated its significance on predicting HCC survival by univariate and multivariate analyses. Furthermore, our results confirmed that miR-302a-3p can directly inhibit the proliferation, migration, and invasion processes of HCC cells. Besides the predictive role, miR-302a-3p was also reported to enhance the drug sensitivity in both breast cancer cells.[@b23-ott-11-8175],[@b24-ott-11-8175] Therefore, it is highly likely that miR-302a-3p may also increase the chemotherapy sensitivity of HCC cells, which needs further evidence. Additionally, our results provided evidence on the direct inhibiting role of miR-302a-3p on the PRKACB, thus attenuating the PKA activity. The phosphorylation levels of Src and CREB, two well-known oncoproteins regulated by PKA, were also inhibited by miR-302a-3p overexpression. It is thus reasonable that miR-302a-3p may suppress HCC progression at least partially by impairing PKA signaling.

To the best of our knowledge, this is the first study on tissue expression and clinical significance of miR-302a-3p in HCC. The inhibitory effect of miR-302a-3p on HCC progression deserves more attention, and it may be an invaluable direction for novel therapy development.

Conclusion
==========

Our data showed that low miR-302a-3p level is an independent prognostic factor for predicting poorer OS of HCC patients, and miR-302a-3p suppressed HCC progression by directly inhibiting tumor cell proliferation and invasion capacities.
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![miR-302a-3p was downregulated in HCC tissues.\
**Notes:** Tissue expression of miR-302a-3p was measured by RT-qPCR for both HCC tumor tissues and adjacent normal liver tissues. (**A**) Most of the patients (74/111, 66.7%) showed a lower miR-302a-3p level in HCC tissues compared with that in normal liver tissues. By paired Student's *t*-test, its downregulation was revealed to be statistically significant (*P*=0.005). (**B**) The mean expression level of miR-302a-3p in HCC tumor tissues was \~20% lower than that in normal liver tissues, further indicating its possible role in tumor suppression. \**P*\<0.05 compared to liver group.\
**Abbreviations:** miR, microRNA; HCC, hepatocellular carcinoma; RT-qPCR, real-time quantitative polymerase chain reaction.](ott-11-8175Fig1){#f1-ott-11-8175}

###### 

OS plots by the Kaplan--Meier analysis and logrank test.

**Notes:** The effects of age (**A**), sex (**B**), HBV infection (**C**), serum AFP (**D**), tumor number (**E**), tumor size (**F**), portal vein invasion (**G**), TNM stage (**H**), and miR-302a-3p level (**I**) on the OS of HCC patients were tested by the Kaplan--Meier method and logrank test. Accordingly, prognostic factors included tumor number (*P*=0.006), tumor diameter (*P*=0.015), portal vein invasion (*P*=0.010), TNM stage (*P*\<0.001), and miR-302a-3p level (*P*=0.002). \**P*\<0.05 by Kaplan--Meier test.

**Abbreviations:** OS, overall survival; miR, microRNA; HCC, hepatocellular carcinoma.
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###### 

Effects of miR-302a-3p on the tumoral phenotypes of HCC cells.

**Notes:** Overexpressing miR-302a-3p mimics significantly attenuated the proliferation of HepG2 (**A**) and Huh7 (**B**) cells according to the MTT experiments. The migration capacities of HepG2 (**C**) and Huh7 (**D**) cells were inhibited by transfecting miR-302a-3p mimics. Similarly, Matrigel transwell results demonstrated the suppressing role of miR-302a-3p in inhibiting HCC invasion capacity (**E** and **F**). Graphs were generated from three independent experiments. \**P*\<0.05 by Student's *t*-test.

**Abbreviations:** miR, microRNA; HCC, hepatocellular carcinoma.
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###### 

miR-302a-3p directly suppresses PRKACB signaling.

**Notes:** (**A**) The putative miR-302a-3p binding site with PRKACB was predicted by TargetScan ([www.targetscan.org](http://www.targetscan.org)). (**B**) The luciferase activity of WT PRKACB was inhibited by miR-302a-3p; however, miR-302a-3p showed no significant effect on the luciferase activity of the mutant PRKACB (mutated the binding sites shown in \[**A**\]). \**P*\<0.05. (**C**) Western blot showed the effect of miR-302a-3p on inhibiting the expression of PRKACB, as well as the activation of PKA downstream effectors. (**D**) A schematic model showed our hypothetical mechanism of miR-302a-3p on suppressing liver cancer progression. refers to the phosphate group in biochemistry concept.

**Abbreviations:** miR, microRNA; WT, wild type; UTR, untranslated region.
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###### 

Clinical characteristics of the HCC patients

  Clinicopathologic features   Case number   Percentage
  ---------------------------- ------------- ------------
  Age (years)                                
   ≤50                         62            55.9
   \>50                        49            44.1
  Sex                                        
   Female                      20            18.0
   Male                        91            82.0
  HBV                                        
   Negative                    24            21.6
   Positive                    87            78.4
  Serum AFP                                  
   ≤400 U/mL                   39            35.1
   \>400 U/mL                  72            64.9
  Tumor number                               
   Single                      72            64.9
   Multiple                    39            35.1
  Tumor diameter (cm)                        
   ≤5.0                        42            37.8
   \>5.0                       69            62.2
  Portal vein invasion                       
   Negative                    80            72.1
   Positive                    31            27.9
  TNM stage                                  
   I--II                       44            39.6
   III--IV                     67            60.4
  miR-302a-3p level                          
   Low                         74            66.7
   High                        37            33.3

**Abbreviations:** HCC, hepatocellular carcinoma; miR, microRNA.

###### 

Correlations between miR-302a-3p level and clinico-pathological variables

  Variables              miR-302a-3p level   *P*-value   
  ---------------------- ------------------- ----------- -----------------------------------------------------
  Age (years)                                            
   ≤50                   42                  20          0.787
   \>50                  32                  17          
  Sex                                                    
   Female                16                  4           0.162
   Male                  58                  33          
  HBV                                                    
   Negative              13                  11          0.142
   Positive              61                  26          
  Serum AFP                                              
   ≤400 U/mL             26                  13          1.000
   \>400 U/mL            48                  24          
  Tumor number                                           
   Single                41                  31          0.003[\*](#tfn2-ott-11-8175){ref-type="table-fn"}
   Multiple              33                  6           
  Tumor diameter (cm)                                    
   ≤5.0                  15                  27          \<0.001[\*](#tfn2-ott-11-8175){ref-type="table-fn"}
   \>5.0                 59                  10          
  Portal vein invasion                                   
   Negative              51                  29          0.295
   Positive              23                  8           
  TNM stage                                              
   I--II                 24                  20          0.028[\*](#tfn2-ott-11-8175){ref-type="table-fn"}
   III--IV               50                  17          

**Note:**

*P*\<0.05 by Chi-square test.

**Abbreviation:** miR, microRNA.

###### 

Kaplan--Meier survival analysis for HCC patients

  Variables                3-year OS (%)   OS months (mean±SD)   *P*-value
  ------------------------ --------------- --------------------- -----------------------------------------------------
  Age (years)                                                    
   ≤50                     72.5            31.1±2.4              0.840
   \>50                    56.9            30.7±3.0              
  Sex                                                            
   Female                  38.9            28.2±3.5              0.514
   Male                    78.7            31.4±2.2              
  HBV                                                            
   Negative                51.5            35.0±4.5              0.256
   Positive                76.0            29.7±2.0              
  Serum AFP                                                      
   ≤400 U/mL               41.6            34.5±3.2              0.170
   \>400 U/mL              37.4            28.8±2.3              
  Tumor number                                                   
   Single                  49.2            34.7±2.4              0.006[\*](#tfn4-ott-11-8175){ref-type="table-fn"}
   Multiple                19.4            23.5±2.4              
  Tumor diameter (cm)                                            
   ≤5.0                    47.9            36.4±3.0              0.015[\*](#tfn4-ott-11-8175){ref-type="table-fn"}
   \>5.0                   32.8            26.5±1.9              
  Portal vein invasion                                           
   Negative                45.6            33.2±2.1              0.010[\*](#tfn4-ott-11-8175){ref-type="table-fn"}
   Positive                0.00            21.2±2.3              
  TNM stage                                                      
   I--II                   61.8            39.1±2.7              \<0.001[\*](#tfn4-ott-11-8175){ref-type="table-fn"}
   III--IV                 19.4            23.8±1.8              
  miR-302a-3p expression                                         
   Low                     28.2            25.6±1.7              0.002[\*](#tfn4-ott-11-8175){ref-type="table-fn"}
   High                    58.7            38.8±3.2              

**Note:**

*P*\<0.05 by Chi-square test.

**Abbreviations:** HCC, hepatocellular carcinoma; OS, overall survival; miR, microRNA.

###### 

Multivariate analysis of HCC patients

  Variables              HR (95% CI)            *P*-value
  ---------------------- ---------------------- ---------------------------------------------------
  Tumor number           1.486 (0.612--3.608)   0.382
  Tumor diameter         2.053 (0.910--4.632)   0.083
  Portal vein invasion   2.513 (0.985--6.411)   0.054
  TNM stage              2.339 (1.748--4.290)   0.024[\*](#tfn6-ott-11-8175){ref-type="table-fn"}
  miR-302a-3p level      0.480 (0.249--0.894)   0.039[\*](#tfn6-ott-11-8175){ref-type="table-fn"}

**Note:**

*P*\<0.05 by Cox regression test.

**Abbreviations:** HCC, hepatocellular carcinoma; miR, microRNA.
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